Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab plus gemcitabine-based chemotherapy for unresectable or metastatic pancreatic and biliary tract cancers
ChiCTR2100049181Phase 2Not yet recruiting
- Sponsor
- Peking University International Hospital
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nimotuzumab in pancreatic cancer (PC), biliary cancer and cholangiocarcinoma (CCA), sponsored by Peking University International Hospital. Primary endpoints: objective response rate, disease control rate and 4 more. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
nimotuzumab
03
Conditions
pancreatic cancer (PC)biliary cancercholangiocarcinoma (CCA)
Beyond the preview
Go deeper on ChiCTR2100049181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049181.